SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes. Patel T. Ann Intern Med 2023 Mar 7. doi: 10.7326/J23-0002.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Patel T. SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes. Ann Intern Med 2023 Mar 7. doi: 10.7326/J23-0002.
PMID: 36877973